With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.23462-75-1,Dihydro-2H-pyran-3(4H)-one,as a common compound, the synthetic route is as follows.
Example 26A 6,7-dihydro-5H-pyrano[3,2-d]thiazol-2-amine A mixture of dihydro-2H-pyran-3(4H)-one (0.5 g, 5.0 mmol, Small Molecules Inc), piperidine (0.5 mL, 5.0 mmol, Aldrich) and p-toluenesulfonic acid monohydrate (10 mg, 0.05 mmol) in cyclohexane (20 mL) was refluxed for 6 h with a Dean-Stark trap. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in methanol (10 mL). To the above solution were added sulfur (0.16 g, 5.0 mmol) and a solution of cyanamide (0.21 g, 5.0 mmol) in methanol (3 mL) at 0 C. The reaction mixture was stirred at room temperature for 16 h and then concentrated under reduced pressure. The residue was purified by column chromatography using an Analogix Intelliflash280 (SiO2, 0-5% methanol in methylene chloride) to obtain 60 mg of a product containing two regioisomers (6,7-dihydro-4H-pyrano[3,4-d]thiazol-2-amine (Example 8A) and the title compound 6,7-dihydro-5H-pyrano[3,2-d]thiazol-2-amine (3:1)). MS (ESI+) m/z 157 (M+H)+., 23462-75-1
The synthetic route of 23462-75-1 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; Abbott Laboratories; US2008/287510; (2008); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics